NCT01068873 - Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

HIV Infections

Interventions

DRUG

lopinavir/ritonavir plus maraviroc

Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.

Trial Locations (1)

19140

Temple General Internal Medicine, Philadelphia